Kornimate/medical-research-clean huggingface dataset:
effects of heating massaging vibrating vicinity of the insulin delivery site

Conditions: DIABETES

Summary: the aim of this experiment is to test the pharmacodynamics and pharmacokinetics of insulin analogs and their dependence on external and physiological alterations. the investigators plan compare the pharmacodynamics of insulin analog delivery in regular conditions and in the presence of increased perfusion of the delivery site, achieved by way of local warming, movement and topical application of capsaicin cream. the investigators will also test the effect of local heating and topical application of capsaicin cream on the post prandial glucose levels following a bolus.


Eligibility criteria:
inclusion criteria: 1. participant age between 18- 65 years old 2. type i or type ii diabetes 3. hba1c 6-12% 4. does not suffer from sever hypertension, kidney, liver or heart disease 5. does not suffer from active ischemic heart disease 6. is willing to sign the consent form exclusion criteria: 1. participants age \ 65 2. pregnancy 3. breast feeding women 4. un-controlled diabetes, hba1c values \> 12% range 5. suffers from active ischemic heart disease 6. alcohol addiction 7. is not prepared to signed the informed consent

Keywords: diabetes pharmacokinetics pharmacodynamics insulin
efficiency of bumetanide in autistic children

Conditions: Autistics Children

Summary: the purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism


Eligibility criteria:
inclusion criteria: * children from 3 to 10 years old, answering the diagnosis of typical autism according to the diagnostic criteria of autism of the classification of the who ( cim-10) and the parents of which gave a free, enlightened and written consent. exclusion criteria: * patients epileptic autistics treated by anticomitiaux or having hurts of the central nervous system * patients autistics receiving a psychotropic treatment * patients presenting disorders electrolytes * patients presenting a hypersensibility known about sulpha drugs * presenting patients against indications relative to the treatment by bumetanide * patients already treated by diuretics * patients presenting a hepatic or renal incapacity * patients presenting an elongation of the qt to the electrocardiogram. * patients autistics of cars sore is lower than 30.

Keywords: autism bumetanide gaba nkcc1
dog assisted therapy: comparing duration treatments for patients with fetal alcohol spectrum disorder

Conditions: Fetal Alcohol Spectrum Disorders

Summary: the objective of the present study was to assess the efficacy of a shorter version program of dog assisted therapy (dat) (8 sessions) compared to a longer version (16 sessions) for children and adolescents with fetal alcohol syndrome (fasd). we evaluated the impact of dat on social skills, internalizing and externalizing problems, quality of life, severity of the disorder and emotional well-being of parents. we conducted a randomized controlled trial in a cohort of 55 patients with fasd.

fasd can be classified into three subtypes. fas is identified by (1) facial abnormalities, (2) growth deficits, abnormal brain development, or irregularities in neurophysiology, and (3) neurobehavioral issues. partial fetal alcohol spectrum disorder (fasd) shares similarities but presents with fewer physical characteristics, while alcohol-related neurobehavioral disorder (arnd) solely exhibits neurobehavioral symptoms without facial anomalies. previous research has highlighted the effectiveness of psychological intervention programs focused on emotional regulation for individuals with fasd. similarly, studies have emphasized the benefits of interventions targeting social skills. these interventions have been shown to result in reductions in externalizing behaviors, with social skills training specifically correlating with improvements in social competence and a decrease in problematic behaviors recently a new form of behavioral therapy has been gaining popularity in improving the physical and mental health of young adults, known as animal assisted therapy (aat). animal assisted therapy lays its foundation in human attachment theory and social cognitive theory where it is argued that animals can be potentially viewed as a transitional attachment object and thus aid to improve psychosocial functioning.

Eligibility criteria:
inclusion criteria:all participants needed to have stable doses of medication for at least two months before the study and agree not to seek out any other psychiatric or psychological treatment during the study. - exclusion criteria:patients who were not behaviorally stable, presented agressive behavior or required more intensive treatment (hospitalization or day hospital) were excluded. -
effect of acetazolamide on right heart function at rest in lowlanders older than 40 years at altitude.

Conditions: Altitude Hypoxia

Summary: randomized, placebo controlled trial evaluating efficacy of acetazolamide on right heart function at rest in lowlanders older than 40 years travelling from 760 m to 3'100 m.

this is a randomized, placebo-controlled, double-blind parallel trial evaluating the efficacy of preventive acetazolamide intake on right heart function at rest in lowlanders older than 40 years travelling to altitude. participants living in the bishkek area, kyrgyzstan (760m), will be transferred by car within 4h to the tuja ashu high altitude clinic (3'100 m), and stay there for 2 days. acetazolamide 375mg/day (or placebo), will be administered before departure at 760 m and during the stay at altitude. outcomes will be assessed during the stay at 3'100 m. an interim analysis will be carried out when 200 participants will have completed the study and/or after the first year. the peto's method will be used and the trial will be stopped when pre-specified futility boundaries were crossed.

Eligibility criteria:
inclusion criteria: * healthy men and women, age 40-75 yrs, without any disease and need of medication. * born, raised and currently living at low altitude (\<800m). * written informed consent. * kyrgyz ethnicity exclusion criteria: * any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. * any condition that may interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day or \>20 pack-years with active smoking during the last 10 years), regular use of alcohol. * allergy to acetazolamide and other sulfonamides.

Keywords: healthy participants older than 40 years right heart function prevention acetazolamide
is patients with pulmonary disease benefit a program with yogic exercises?

Conditions: COPD; Asthma

Summary: is yogic exercises (12 weeks) increasing respiratory function, functional capacity and quality of life in patients with obstructive lung diseases. with follow up after 6 months.

is yogic exercises increasing respiratory function in patients with obstructive lung diseases. will ye improve respiratory muscle strength, functional capacity, inspiratory and expiratory pressure, lung function, perceived dyspnea, dyspnea-related distress (dd), less frequency of dyspnea and heart rate variability in patients with pulmonary disease. qualitative content analysis will be performed on approximately 15 interviews with patients participated in the yoga group about their experiences and their benefits perceived/experienced of the yogic exercises we want to try ye as an alternative treatment in patients with mild to severe pulmonary disease.

Eligibility criteria:
inclusion criteria: * mild to severe pulmonary obstructions according to gold 1-3 (global initiative for chronic obstructive lung disease), * fev (forced expiratory volume) in one second (fev1) % of predicted respiratory function (30% ≤ fev1 ≤ 90%) * fev1/fvc \< 0.70 (\<65 over 65 yrs). \*fvc=forced vital capacity exclusion criteria: * severe neurological, orthopedic or rheumatologic injuries * severely decreased thorax mobility and lung function. * severe lung diseases * other chronic diseases that will interfere with performance. * under 200 meters on the 6mwt * acute dyspnea * surgery within 6 months * medication affecting attention, sudden change of medication.
a clinical study of the c8 medisensors optical glucose monitor™

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to compare glucose measurements from the c8 medisensors non-invasive optical glucose monitor™ system to blood glucose measurements from the yellow springs instrument(ysi) blood glucose analyzer.

this is a prospective, non-randomized, open label study to evaluate the performance of the c8 medisensors non-invasive optical glucose monitor™ on individuals with diabetes mellitus. capillary blood samples will be obtained throughout a daily study session; the study session may last for up to 12 hours. blood glucose will be measured on a ysi blood glucose analyzer. subjects may adjust food intake and insulin administration so device performance is evaluated across a broad range of glucose concentrations. glucose measurements will be time matched and paired for comparison. skin effects and adverse events will be evaluated.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older. 2. understands and agrees to comply with study instructions. 3. read, understood, signed and dated the informed consent form. exclusion criteria: 1. pregnancy. 2. extensive skin changes or diseases that preclude wearing the test device at the proposed wear site(s) (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis). 3. employed by a company within the diabetes field other than the study sponsor. 4. medical history or any condition that may, in the opinion of the investigator, compromise the subject's ability to participate.

Keywords: diabetes diabetes mellitus continuous glucose monitor
imaging study on halcyon 4.0 system for patients receiving radiation therapy

Conditions: Brain Cancer; Head and Neck Cancer; Lung Cancer; Gastric Cancer; Ovarian Cancer; Colon Cancer

Summary: this prospective imaging study is evaluating the feasibility of using the halcyon 4.0 radiotherapy system for radiation therapy planning in patients with cancer. the halcyon 4.0 system has been engineered to decrease the image acquisition time and the radiation exposure, but the system has not yet been clinically validated for use in radiation planning. this pilot study will evaluate images obtained on the halcyon 4.0 system to assess if the quality is sufficient for radiation treatment plan construction.


Eligibility criteria:
eligibility criteria: * planning to receive radiation therapy to one of the following sites: * head and neck/brain (n=10) * thorax (n=10) * abdomen (n=10) * pelvis (n=10) * at least 18 years of age * if the patient will be receiving iv contrast on study: adequate renal function as defined by a serum creatinine \< 1.4, or, for patients with chronic kidney disease, a stable serum creatinine \< 2.0. note: if no iv contrast will be administered on study, patient may enroll without creatinine level documented. * if the patient is a woman of childbearing potential, a negative pregnancy test must be obtained. contraceptive use is not an adequate documentation of no chance of pregnancy. * able to understand and willing to sign an irb approved written informed consent document.

Keywords: radiation therapy halcyon brain radiation thoracic radiation abdominal radiation pelvic radiation
post-ca neuroprotection with magnesium

Conditions: Cardiac Arrest; Return of Spontaneous Circulation

Summary: the purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved return of spontaneous circulation (rosc) following cardiac arrest (ca). the primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.


Eligibility criteria:
inclusion criteria: * documented post-cardiac arrest patient with return of spontaneous circulation (rosc) achieved \<2 hours prior to recruitment exclusion criteria: * age \ 85 years * traumatic cardiac arrests * unsustained rosc (\<20 minutes) * patient who is responsive/able to follow motor commands within 1 hour of achieving rosc * plan for withdrawal of life support within 72 hours of rosc * known pregnant women at the time of the cardiac arrest * known prisoners at the time of the cardiac arrest * subjects who have a medical o social condition that would make them inappropriate for the study based on the pi's or clinical team judgement.
the effect of oxytocin on placebo analgesia: an experimental study in healthy volunteers

Conditions: Mechanisms and Modulators of Placebo Analgesia in Healthy Volunteers

Summary: placebo responses contribute to medical treatment outcome. the purpose of this study is to determine whether a single intranasal application of oxytocin can increase the placebo response in an experimental model of placebo analgesia in healthy volunteers.

placebo responses contribute to medical treatment outcome. the purpose of this study is to determine whether a single intranasal application of oxytocin can increase the placebo response in an experimental model of placebo analgesia in healthy volunteers. the rationale to study the effects of oxytocin on placebo analgesia is based on previous studies showing that oxytocin fosters processes such as empathy, trust and social learning, which are key elements of the patient-physician relationship that is pivotal to placebo responses. in this experimental mechanisms study we used oxytocin as a tool to modulate these factors. placebo analgesia is induced verbal instruction. therefore two identically looking placebo ointments were applied to two sites of the participants' volar forearm. the ointments were introduced as a local anesthetic that could reduce or even abolish pain (placebo) and a control cream (control), respectively.

Eligibility criteria:
inclusion criteria: * healthy volunteers, male and female * being german-speaking * agreeing to participate, verified by completion of informed consent exclusion criteria: * acute or chronic pain condition * use of any concomitant medication except contraceptives * currently pregnant (verified by urine pregnancy test) or lactating * major mental disorder * inability to comply with the study procedures * abnormal pain sensitivity as indicated by pain threshold * alcohol intake within last 24 hours

Keywords: pain pain modulation placebo analgesia
value of manual therapy specificity referred to pain intensity in patients with subacute and unspecified low back pain

Conditions: Low Back Pain

Summary: this study proves the specificity of manual therapy in unspecified an subacute low back pain

the purpose of the study is to determine the importance of manual therapy specificity in relation to subacute low back pain. in order to do this, it will be selected a sample of at least 48 people who suffer low back pain whose duration has not exceeded 12 weeks. patients will be divided into two groups and a different physiotherapist from the one who will subsequently perform the intervention, will assess and determine which is the most painful segment in each of them. in the first group, the intervention to be carried out will be through posteroanterior (pa) vertebral mobilizations in the most painful lumbar segment. the members of the second group will undergo this same technique on a painful segment of the region adjacent to the one they have referred as the main source of pain. each of these sessions will continue until the patient's symptoms have decreased two points on the numerical scale of pain. there will be one session per week, for six weeks. to determine the differences between the two groups, there will be carried out 4 measurements of pain, functional disability, quality of life and kinesiophobia, and 3 measurements of pressure pain threshold were performed. each one of them will be carried out in the first session, in the third week of treatment, in the last session of the treatment and one month after the end of the treatment. the last measeurement will be executed online and that is why the pressure pain threshold will be measured three times while the rest will be do it. the hypothesis is that it won´t be differences in the amount of pain between the tratment on the main painful segment and the treatment on his adyacent segment.

Eligibility criteria:
inclusion criteria: * people aged between 18 and 65 years old with unspecific and subacute low back pain. * participants must be capable of walking twice a week 20 minutes per day. exclusion criteria: * people with history of spinal surgeries, osteoporosis and tumor. * pregnant and people with severe respiratory and cardiac illness.

Keywords: low back pain subacute manual therapy pa mobilization manipulation
acceptability and feasibility of transcranial magnetic stimulation (tms) for depression in multiple sclerosis

Conditions: Multiple Sclerosis; Major Depressive Disorder; Treatment Resistant Depression

Summary: the goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of tms for the treatment of depression in people with ms. participants will receive outpatient tms treatment over the course of 5-6 weeks. participants will complete validated questionnaires and exams before, during, and after treatment.

multiple sclerosis (ms) is a chronic, immune-mediated disease of the central nervous system. depression, or major depressive disorder, is highly prevalent in people with ms and often has a serious impact on quality of life. mdd can be difficult to treat with medications in ms. transcranial magnetic stimulation (tms) is a safe and approved treatment for treatment-resistant depression in the general population. however, little is known about the use of tms for mdd in people with ms. this pilot study will evaluate the safety, feasibility, and preliminary efficacy of tms for mdd in ms. participants will receive outpatient neuronavigated-tms for mdd. various measures of ms and mdd symptoms will be monitored over the course of treatment. clinical brain imaging will also be compared before and after tms.

Eligibility criteria:
inclusion criteria: * established diagnosis of multiple sclerosis (any subtype) by 2017 mcdonald criteria * established diagnosis of major depressive disorder (mdd) by dsm-5 criteria * eligible for transcranial magnetic stimulation (rtms) for depression exclusion criteria: * ms relapse and/or steroid use within 3 months * active suicidal ideation * history of seizure/epilepsy, brain tumor, or stroke * history of bipolar disorder or psychosis * currently or planning to become pregnant

Keywords: multiple sclerosis depression major depressive disorder treatment resistant depression transcranial magnetic stimulation tms
dynamic coronary roadmap for contrast reduction

Conditions: Coronary Artery Disease

Summary: the dynamic coronary roadmap is a commercially available product developed by philips medical systems, a philips healthcare company. dynamic coronary roadmap is a software medical device intended to provide a real-time and dynamic angiographic roadmap of coronary arteries. the angiographic roadmap is automatically generated from previously acquired coronary angiograms during the same procedure. dynamic coronary roadmap overlays the angiographic roadmap on live 2d fluoroscopic images, thereby assisting the physician in navigating devices, e.g. (guide) wires, catheters, through the coronary arteries. this is a multi-center, prospective, unblinded, stratified 1:1 randomized controlled trial to assess whether using dynamic coronary roadmap reduces the total iodinated contrast volume related to percutaneous coronary intervention (pci) compared to the control group without dynamic coronary roadmap.

primary objective: • to assess whether using dynamic coronary roadmap reduces the total iodinated contrast volume related to percutaneous coronary intervention (pci) compared to the control group without dynamic coronary roadmap. secondary objective: • to assess the total number of contrast enhanced cine angiographic x-ray runs (angiograms) related to percutaneous coronary intervention (pci) in the dynamic coronary roadmap and control group

Eligibility criteria:
inclusion criteria: * subject is undergoing percutaneous coronary intervention (pci) with a degree of complexity that anticipates the need for more than 25ml of iodinated contrast volume * subject has signed informed consent * subject is 18 years of age or older, or of legal age to give informed consent per state or national law exclusion criteria: * subject undergoing emergency percutaneous coronary intervention (pci) * subject with st-segment elevation myocardial infarction (stemi) * subject with chronic total occlusion (cto) * subject undergoing pci for isolated ostial disease of left main coronary artery (lmca) or right coronary artery (rca) * subject undergoing percutaneous coronary intervention (pci) with optical coherence tomography (oct) support * subject undergoing percutaneous coronary intervention (pci) with rotational or orbital atherectomy * subject with chronic kidney disease (ckd) stage v (estimated glomerular filtration rate (egfr) \< 15 ml/min/1.73 m\^2) * subject with contrast allergy that cannot be adequately pre-medicated * subject participates in a potentially confounding drug or device trial during the course of the study. * subject is under 18 years of age, or pregnant woman, or breast feeding woman, or meets an exclusion criteria according to national law
intravesical chemotherapy treatment of superficial bladder cancer

Conditions: Bladder Neoplasms

Summary: this is a phase ii study where chemotherapy (gemcitabine) is given into the urinary bladder.


Eligibility criteria:
inclusion criteria: * superficial bladder cancer * no prior chemotherapy exclusion criteria: * grade 3 tumors * papillary tumors invading connective tissue * significant urologic disease, possible interfering with intravesical therapy